Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant IBI310 + Sintilimab + Chemoradiotherapy for Locally Advanced Esophageal Cancer
NCT07751055Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab, sintilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Sun Yat-sen University. Started Aug 2026; status: recruiting.
02
Drugs
ipilimumabsintilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07751055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07751055.